Antheia
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $2.0m | Seed | |
* | $230k | Grant | |
N/A | $6.2m | Early VC | |
N/A | $9.5m | Series A | |
$1.2m | Grant | ||
N/A | $9.2m | Early VC | |
$73.0m | Series B | ||
* | $40.0m | Debt | |
* | $17.0m | Grant | |
Total Funding | $118m |
Recent News about Antheia
EditAntheia is a science and technology company focused on developing next-generation plant-inspired medicines. By leveraging synthetic biology, genomics, informatics, and fermentation, Antheia harnesses beneficial molecules from plants to create active pharmaceutical ingredients (APIs) in more controlled and economical ways. The company aims to disrupt the traditional agriculture-based supply chain, creating more equitable distribution channels and accelerating the discovery of new medicines. Antheia serves pharmaceutical companies and operates in the biotechnology and pharmaceutical markets. Its business model revolves around the development and sale of APIs, making money through partnerships, licensing agreements, and direct sales.
Keywords: synthetic biology, genomics, fermentation, plant-inspired medicines, active pharmaceutical ingredients, biotechnology, pharmaceutical, controlled production, economical APIs, equitable distribution.